Loading candles…
Innova Captab Ltd, incorporated in January 2005, is an integrated pharmaceutical company based in India. It operates across the entire pharmaceutical value chain, including research and development, manufacturing, and marketing. The company’s business segments include Contract Development and Manufacturing Organization (CDMO) services, domestic branded generics, and international branded generics. Innova Captab serves over 200 CDMO customers as of fiscal year 2025 and maintains a broad distribution network throughout India. It focuses solely on the pharmaceutical industry and does not have any listed subsidiaries or ventures.
This page is a live market overview for INNOVA CAPTAB LIMITED (INNOVACAP) on the NSE. As a listed security, INNOVA CAPTAB LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for INNOVACAP before placing trades on tick2trade.
As of the latest feed, INNOVACAP last traded at ₹944.5 on NSE, down ₹9.55 (1.00%) from the previous close of ₹954.05. Today's session range is ₹937.5 – ₹959.7, against a 52-week band of ₹622 – ₹1,034.85. Traded volume today stands at 20.53K shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for INNOVACAP in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether INNOVACAP is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for INNOVA CAPTAB LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in INNOVACAP. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated INNOVACAP option chain page linked from this overview.
| Results - FY26 |
| To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 7 May 2026 |
| Unaudited Results - Q3-FY15 | Intimation of Board Meeting under Regulations 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (i) for consideration of Una… | 23 Jan 2026 |
| Results - Q2 & FY25 | To consider and approve the financial results for the quarter and half year ended September 30, 2025 and other business matters | 7 Nov 2025 |
| Unaudited Results - Q1-FY25 | Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board… | 7 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve the audited financial results for the quarter and year ended March 31, 2025 and other business matters | 19 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.